Rapid Therapeutic Science Laboratories, Inc.

RTSL

RTSLRapid Therapeutic Science Laboratories, Inc. US flag

Other OTC

0.00

USD

+0.00

(+2.56%)

0.01EPS

0.40P/E

-NaNMarket Cap

Mar 31Next Earn

CIK

0001575659

ISIN

US7534312043

CUSIP

753431105

Return %

Stock

S&P500

-27.27

9.99

-98.46

59.68

-98.57

94.43

Use logarithmic scale

	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	TTM
Revenue per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Basic EPS, GAAP	- -	-0.17	-0.11	-0.11	-0.2	-25.88	-7.24	-0.26	-0.38	-0.23	0.01
Free Cash Flow per Basic Share	- -	-0.12	-0.08	-0.1	-0.2	-1.71	-2.21	-0.14	-0.33	-0.15	-0.03
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	- -	-0.24	-0.36	-0.47	-0.67	-26.63	-61.79	-1.43	-1.12	-1.33	-1.26
Tangible Book Value per Share	- -	0.21	0.1	-0.01	-0.21	-29.06	-65.79	-0.69	-0.2	-0.43	-0.36
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	2	8	8	8
Sales/Revenue/Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	-4,737.97	-407,471.54	- -	- -
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	- -	- -	- -	- -	- -	-3	- -	-1	-3	-2	- -
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	- -	- -	- -	- -	- -	- -	- -	-6,834.27	-537,056.74	- -	- -
Working Capital	- -	- -	- -	- -	- -	-1	-1	-1	-3	-5	-4
LT Debt	- -	- -	- -	- -	- -	2	2	- -	1	- -	- -
Total Equity	- -	- -	- -	- -	- -	-3	-3	-1	-1	-3	-3
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	-67.21
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	-10.04
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	- -
Net Income, GAAP	- -	2,404.95%	-37.42%
Free Cash Flow	- -	286.01%	-52.4%
Total Cash Common Dividend	- -	- -	- -
Total Equity	- -	2,496.06%	127.35%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Donal R. Schmidt Jr.
Full Time Employees: 3
Sector: Healthcare
Industry: Medical - Devices
Address: 5580 Peterson Lane Dallas TX United States of America 75201
IPO Date: Jun 14, 2017
CIK: 0001575659
Website: rtslco.com
Similar Companies: Visioneering Technologies, Inc. (VTI.AX)
Cell Kinetics Ltd. (CKNTF)
FluroTech Ltd. (FLURF)
Össur hf. (OSSFF)
Vapotherm, Inc. (VAPO)
Synektik Spólka Akcyjna (SNT.WA)
Business: Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc.

Company News

globenewswire.com
4 years ago
Rapid Therapeutic Science Laboratories to Present at the Q4 Investor Summit Conference

	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	TTM
Revenue per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Basic EPS, GAAP	- -	-0.17	-0.11	-0.11	-0.2	-25.88	-7.24	-0.26	-0.38	-0.23	0.01
Free Cash Flow per Basic Share	- -	-0.12	-0.08	-0.1	-0.2	-1.71	-2.21	-0.14	-0.33	-0.15	-0.03
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	- -	-0.24	-0.36	-0.47	-0.67	-26.63	-61.79	-1.43	-1.12	-1.33	-1.26
Tangible Book Value per Share	- -	0.21	0.1	-0.01	-0.21	-29.06	-65.79	-0.69	-0.2	-0.43	-0.36
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	2	8	8	8
Sales/Revenue/Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	-4,737.97	-407,471.54	- -	- -
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	- -	- -	- -	- -	- -	-3	- -	-1	-3	-2	- -
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	- -	- -	- -	- -	- -	- -	- -	-6,834.27	-537,056.74	- -	- -
Working Capital	- -	- -	- -	- -	- -	-1	-1	-1	-3	-5	-4
LT Debt	- -	- -	- -	- -	- -	2	2	- -	1	- -	- -
Total Equity	- -	- -	- -	- -	- -	-3	-3	-1	-1	-3	-3
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	-67.21
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	-10.04
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

Rapid Therapeutic Science Laboratories, Inc.

Growth Rates

(avg. rate of change)

Company Description

Company News

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year

	Dec'22	Mar'23	Jun'23
ST Debt	3	3	3
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	8	8	9
Market Capitalization	6	1	1

	Dec'22	Mar'23	Jun'23
Total Current Assets	- -	- -	- -
Accounts Receivable, Net	- -	- -	- -
Cash, Cash Equivalents & STI	- -	- -	- -
Inventories	- -	- -	- -
Total Current Liabilities	5	4	4
Payables & Accruals	1	1	1
ST Debt	3	3	3
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2021	-0.08	- -	-0.07	-0.07	-0.38
2022	-0.2	- -	-0.03	- -	-0.23
2023	0.02	0.01	- -	- -	- -